EP Patent

EP2240489A1 — Preparation and use of (r),(r)-2,2'-bis-methylnaltrexone

Assigned to Progenics Pharmaceuticals Inc · Expires 2010-10-20 · 16y expired

What this patent protects

This invention relates to synthesis of (R),(R)-2,2' -bis-MNTX, as shown in Formula (I), and related methods and products.

USPTO Abstract

This invention relates to synthesis of (R),(R)-2,2' -bis-MNTX, as shown in Formula (I), and related methods and products.

Drugs covered by this patent

methylnaltrexone-bromide (METHYLNALTREXONE BROMIDE)

Patent Metadata

Patent number: EP2240489A1
Jurisdiction: EP
Classification: —
Expires: 2010-10-20
Drug substance claim: No
Drug product claim: No
Assignee: Progenics Pharmaceuticals Inc
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.